1. Microtubules are the molecular target of the antimicrotubule chemotherapy agents. What is the fundamental structural unit from which microtubules are assembled?
A) Single globular actin monomers that polymerize end to end into a solid filament
B) Heterodimers of alpha-tubulin and beta-tubulin that assemble into hollow cylindrical polymers
C) Triple-helical strands of intermediate filament protein cross-linked by desmin
D) Repeating myosin heavy-chain subunits arranged around a central core
E) Covalently linked rings of glial fibrillary acidic protein
ANSWER: B
Rationale:
Microtubules are hollow cylindrical polymers built from heterodimers of alpha-tubulin and beta-tubulin. These heterodimers assemble and disassemble in a process called dynamic instability, rapidly switching between phases of polymerization and depolymerization. This behavior is essential for forming the mitotic spindle and separating chromosomes during cell division, which is why microtubules are an effective chemotherapy target in rapidly dividing tumor cells.
Option A: Option A is incorrect: actin monomers polymerize into microfilaments, a separate cytoskeletal system distinct from microtubules, and microfilaments are not the target of antimicrotubule agents.
Option C: Option C is incorrect: intermediate filaments (which include desmin-containing filaments) are a third cytoskeletal system and are not built from tubulin.
Option D: Option D is incorrect: myosin is a motor protein associated with actin filaments, not a structural subunit of microtubules.
Option E: Option E is incorrect: glial fibrillary acidic protein is an intermediate filament protein found in astrocytes and is unrelated to microtubule structure.
2. Antimicrotubule agents fall into two pharmacologically opposite classes based on how they disrupt microtubule dynamics. Which statement correctly pairs each class with its mechanism?
A) Both vinca alkaloids and taxanes work by stabilizing microtubules and preventing their disassembly
B) Both vinca alkaloids and taxanes work by promoting depolymerization of microtubules
C) Vinca alkaloids stabilize microtubules, whereas taxanes promote depolymerization
D) Vinca alkaloids promote depolymerization, whereas taxanes stabilize microtubules and prevent disassembly
E) Neither class alters polymerization; both act only by inhibiting tubulin gene transcription
ANSWER: D
Rationale:
The two classes act through opposite mechanisms on the same target. Vinca alkaloids (vincristine, vinblastine, vinorelbine) bind the beta-tubulin vinca domain and promote depolymerization, suppressing the growth of microtubules at clinically relevant concentrations and producing complete depolymerization at higher concentrations. Taxanes (paclitaxel, docetaxel, cabazitaxel) and the epothilones bind the taxane domain on beta-tubulin and stabilize the polymer, locking microtubules in a non-dynamic state that prevents the chromosome movements of anaphase. Both ultimately arrest cells in mitosis, but by opposite physical effects on the polymer.
Option A: Option A is incorrect: it describes only the taxane mechanism and wrongly applies it to vinca alkaloids.
Option B: Option B is incorrect: it describes only the vinca alkaloid mechanism and wrongly applies it to taxanes.
Option C: Option C is incorrect: it reverses the two mechanisms.
Option E: Option E is incorrect: antimicrotubule agents act directly on the assembled tubulin polymer, not on tubulin gene transcription.
3. By disrupting microtubule dynamics, antimicrotubule agents block cell division at a specific point in the cell cycle. At which transition do these drugs arrest dividing cells?
A) At the metaphase-to-anaphase transition of mitosis (M phase), where the spindle assembly checkpoint cannot be satisfied
B) At the G1-to-S transition, by blocking entry into DNA synthesis
C) During S phase, by directly inhibiting DNA polymerase
D) At the G0 resting state, by preventing cells from ever entering the cycle
E) During cytokinesis only, after chromosome separation is already complete
ANSWER: A
Rationale:
Antimicrotubule agents disrupt the mitotic spindle so that kinetochores cannot achieve proper attachment to spindle microtubules. This leaves the spindle assembly checkpoint (SAC), the surveillance system that monitors kinetochore attachment, unsatisfied. The SAC inhibits the anaphase-promoting complex/cyclosome and holds the cell at the metaphase-to-anaphase transition. Prolonged mitotic arrest then triggers apoptosis. Because the mechanism requires cells to actually enter mitosis, these agents are M-phase specific and most effective against rapidly proliferating tumors.
Option B: Option B is incorrect: the G1-to-S transition is governed by cyclin-dependent kinases and is not the site of antimicrotubule action.
Option C: Option C is incorrect: S-phase DNA polymerase inhibition describes antimetabolite-type mechanisms, not microtubule-targeting drugs.
Option D: Option D is incorrect: these drugs act on cells that are actively dividing, not on quiescent G0 cells.
Option E: Option E is incorrect: the drugs prevent the chromosome separation of anaphase from ever occurring, so arrest happens before cytokinesis, not selectively during it.
4. Vincristine is distinguished from the other vinca alkaloids by its characteristic dose-limiting toxicity. Which toxicity limits the dose of vincristine?
A) Severe myelosuppression with neutropenia, requiring routine granulocyte colony-stimulating factor support
B) Cardiotoxicity with a cumulative dose-dependent risk of dilated cardiomyopathy
C) Peripheral neurotoxicity, including a progressive length-dependent sensory neuropathy and autonomic effects
D) Pulmonary fibrosis from cumulative alveolar injury
E) Nephrotoxicity with a dose-dependent decline in glomerular filtration
ANSWER: C
Rationale:
Vincristine's dose-limiting toxicity is peripheral neurotoxicity rather than myelosuppression. It binds axonal microtubules in peripheral sensory and motor neurons and impairs axonal transport, producing a progressive, length-dependent, primarily sensory neuropathy. Symptoms begin distally (loss of deep tendon reflexes, especially the ankle jerk, then paresthesias in the feet) and progress proximally with cumulative dose. Autonomic effects such as constipation, urinary retention, and orthostatic hypotension also occur. Because bone marrow tolerance does not limit the dose, vincristine has essentially no upper dose ceiling based on marrow, which makes inadvertent overdose a clinical risk.
Option A: Option A is incorrect: myelosuppression is the dose-limiting toxicity of vinblastine and vinorelbine, not vincristine.
Option B: Option B is incorrect: dose-dependent cardiomyopathy characterizes the anthracyclines, not vincristine.
Option D: Option D is incorrect: pulmonary fibrosis is associated with agents such as bleomycin, not vincristine.
Option E: Option E is incorrect: dose-dependent nephrotoxicity characterizes platinum agents such as cisplatin, not vincristine.
5. Although vinblastine shares the same mechanism of action as vincristine, its dose-limiting toxicity is different. Which toxicity limits the dose of vinblastine?
A) Peripheral sensory neuropathy that is more severe than that seen with vincristine
B) Autonomic neuropathy producing constipation and urinary retention as the dose-limiting effect
C) Hepatic failure from direct hepatocellular toxicity
E) Myelosuppression, predominantly neutropenia, with the nadir occurring about 7 to 14 days after dosing
ANSWER: E
Rationale:
Vinblastine differs from vincristine in that its dose-limiting toxicity is myelosuppression, predominantly neutropenia, with the nadir typically at 7 to 14 days after dosing. Neurotoxicity does occur with vinblastine but is less severe than with vincristine at equipotent doses. This contrast is the central teaching point of the vinca alkaloid class: a shared mechanism but divergent dose-limiting toxicities, driven by differences in tissue distribution and affinity for neural versus hematopoietic microtubule populations.
Option A: Option A is incorrect: vincristine, not vinblastine, has the more severe neuropathy, and neuropathy is not vinblastine's dose-limiting toxicity.
Option B: Option B is incorrect: autonomic neuropathy is characteristic of vincristine and is not the dose-limiting toxicity of vinblastine.
Option C: Option C is incorrect: vinblastine undergoes hepatic clearance and requires dose reduction in hepatic dysfunction, but hepatic failure is not its dose-limiting toxicity.
Option D: Option D is incorrect: hemorrhagic cystitis is associated with cyclophosphamide and ifosfamide, not vinblastine.
6. Conventional paclitaxel is highly hydrophobic and historically required a solubilizing vehicle that is itself responsible for the drug's characteristic acute hypersensitivity reactions. Which vehicle is used to solubilize conventional paclitaxel?
A) Polysorbate 80, which causes a cumulative fluid retention syndrome
B) Cremophor EL (polyoxyethylated castor oil), a surfactant that causes non-IgE-mediated (anaphylactoid) hypersensitivity reactions
C) Human serum albumin, which binds the drug into a nanoparticle and eliminates the need for premedication
D) Propylene glycol, which produces a metabolic acidosis at high infusion rates
E) Liposomal phospholipid encapsulation, which prolongs circulation half-life
ANSWER: B
Rationale:
Conventional paclitaxel is solubilized in Cremophor EL (polyoxyethylated castor oil), a non-ionic surfactant that is itself a potent cause of non-immunoglobulin E (non-IgE)-mediated, or anaphylactoid, hypersensitivity reactions. These reactions occur in roughly 10 to 40% of patients without premedication, manifest within the first 10 minutes of infusion as flushing, urticaria, bronchospasm, and hypotension, and do not require prior sensitization, distinguishing them from classical IgE-mediated anaphylaxis. This vehicle is also why non-PVC tubing is required, because Cremophor EL leaches DEHP plasticizer from polyvinyl chloride tubing.
Option A: Option A is incorrect: polysorbate 80 (Tween 80) is the vehicle for docetaxel and is associated with fluid retention, not conventional paclitaxel.
Option C: Option C is incorrect: albumin binding describes nab-paclitaxel, a separate formulation that eliminates Cremophor EL.
Option D: Option D is incorrect: propylene glycol is not the paclitaxel vehicle.
Option E: Option E is incorrect: conventional paclitaxel is not a liposomal formulation.
7. Docetaxel is formulated in a different vehicle than conventional paclitaxel, and that vehicle produces a characteristic cumulative toxicity. Which vehicle-related toxicity is characteristic of docetaxel?
A) A fluid retention syndrome (edema, pleural effusions, ascites) caused by the polysorbate 80 vehicle, attenuated by dexamethasone premedication
B) An anaphylactoid reaction caused by Cremophor EL, identical to that of conventional paclitaxel
C) Hemolytic anemia from albumin nanoparticle breakdown
D) Acute pancreatitis from the propylene glycol vehicle
E) Photosensitivity dermatitis unique to the liposomal carrier
ANSWER: A
Rationale:
Docetaxel is formulated in polysorbate 80 (Tween 80) rather than Cremophor EL, and this vehicle produces a cumulative fluid retention syndrome with edema, pleural effusions, and ascites. The syndrome is substantially attenuated by premedication with dexamethasone (typically 8 mg twice daily for 3 days starting the day before infusion), which also reduces hypersensitivity. Fluid retention becomes a significant management challenge at cumulative doses above roughly 400 mg/m squared. Docetaxel also causes nail toxicity and a characteristic skin reaction more prominently than paclitaxel.
Option B: Option B is incorrect: Cremophor EL is the conventional paclitaxel vehicle, not docetaxel's, and the anaphylactoid reaction is a paclitaxel/Cremophor feature.
Option C: Option C is incorrect: albumin nanoparticle formulation describes nab-paclitaxel and does not cause hemolytic anemia.
Option D: Option D is incorrect: docetaxel is not formulated in propylene glycol and is not characteristically associated with pancreatitis.
Option E: Option E is incorrect: docetaxel is not a liposomal formulation, and photosensitivity is not its characteristic vehicle toxicity.
8. A patient receiving combined intravenous and intrathecal chemotherapy is inadvertently given a vinca alkaloid by the intrathecal route. What is the expected clinical outcome of this medication error?
A) A transient chemical meningitis that resolves fully with corticosteroids over several days
B) A self-limited radiculopathy with complete recovery once the drug clears the cerebrospinal fluid
C) No clinical effect, because vinca alkaloids do not cross into neural tissue from the cerebrospinal fluid
D) An ascending myeloencephalopathy that is nearly uniformly fatal within days to weeks
E) An immediate but fully reversible flaccid paralysis lasting only hours
ANSWER: D
Rationale:
Inadvertent intrathecal administration of a vinca alkaloid produces an ascending myeloencephalopathy that is nearly uniformly fatal within days to weeks. When the drug is placed directly into the cerebrospinal fluid (CSF), it bypasses the blood-brain barrier that normally protects central neurons, and it is profoundly neurotoxic to those neurons. The course is stereotyped: severe radicular pain within hours, then ascending motor weakness, loss of sphincter control, and progressive paralysis over 24 to 72 hours, ascending to the brain stem with respiratory failure, coma, and death. There is no established effective treatment, so the entire clinical emphasis is on error prevention.
Option A: Option A is incorrect: this is not a transient, fully reversible chemical meningitis; the injury is destructive and progressive.
Option B: Option B is incorrect: the syndrome does not self-resolve once the drug clears; neuronal destruction is irreversible.
Option C: Option C is incorrect: direct intrathecal injection bypasses the blood-brain barrier and is intensely neurotoxic, the opposite of having no effect.
Option E: Option E is incorrect: the paralysis is progressive and fatal, not a brief reversible episode.
9. Nab-paclitaxel was developed to address a major limitation of conventional paclitaxel. What is nab-paclitaxel?
A) A liposome-encapsulated paclitaxel designed to prolong circulation time
B) A prodrug of paclitaxel that is activated by tumor-specific esterases
C) An albumin-bound nanoparticle formulation of paclitaxel that eliminates the Cremophor EL vehicle
D) A combination of paclitaxel with a P-glycoprotein inhibitor in a single vial
E) A pegylated paclitaxel conjugate that reduces renal clearance
ANSWER: C
Rationale:
Nab-paclitaxel (albumin-bound paclitaxel, Abraxane) is a roughly 130-nanometer nanoparticle in which paclitaxel is bound noncovalently to human serum albumin. Binding paclitaxel to albumin eliminates the need for the Cremophor EL solubilization vehicle, so the standard three-drug hypersensitivity premedication protocol and non-PVC tubing are not required. It is reconstituted in normal saline and infused over about 30 minutes. The albumin-binding rationale also invokes albumin transcytosis and SPARC-mediated tumor accumulation, though that targeting advantage has not been validated clinically.
Option A: Option A is incorrect: nab-paclitaxel is an albumin-bound nanoparticle, not a liposomal formulation.
Option B: Option B is incorrect: it is not an esterase-activated prodrug; the active paclitaxel is delivered directly.
Option D: Option D is incorrect: it does not contain a co-formulated P-glycoprotein inhibitor.
Option E: Option E is incorrect: it is not a pegylated conjugate, and its rationale concerns vehicle elimination and delivery, not renal clearance.
10. A patient on a vincristine-containing regimen is monitored at each cycle for early neurotoxicity so that the dose can be adjusted before disabling neuropathy develops. Which finding is the earliest and most reliable clinical indicator of cumulative vincristine neurotoxicity?
A) A rising serum creatine kinase reflecting early myopathic change
B) The onset of constipation as the first detectable autonomic effect
C) Diplopia from early oculomotor cranial nerve involvement
D) Motor weakness presenting as foot drop on the first cycle
E) Loss of the ankle deep tendon reflex (ankle jerk)
ANSWER: E
Rationale:
Vincristine neuropathy is length-dependent and begins distally, so loss of the ankle deep tendon reflex (the ankle jerk) is an early and reliable indicator of cumulative neurotoxicity and should be documented systematically with serial neurological examination before each cycle. Because the neuropathy is cumulative and only partially reversible, detecting this early sign allows dose adjustment before more disabling deficits develop, which is more effective than treating established neuropathy.
Option A: Option A is incorrect: vincristine produces a neuropathy from impaired axonal transport, not a creatine-kinase-elevating myopathy.
Option B: Option B is incorrect: constipation is a common autonomic effect but is not the earliest reliable indicator used for monitoring; loss of ankle reflexes precedes and is more reliably tracked.
Option C: Option C is incorrect: cranial nerve palsies such as diplopia are recognized but uncommon and late, not the earliest sign.
Option D: Option D is incorrect: motor weakness such as foot drop occurs only at higher cumulative doses and is a later, more advanced finding.
11. A patient receiving vincristine develops hyponatremia. Workup shows a low serum osmolality, inappropriately concentrated urine, and clinically normal volume status. Which vincristine-associated syndrome best explains this picture?
A) Cerebral salt wasting with true volume depletion driven by natriuresis
B) Syndrome of inappropriate antidiuretic hormone secretion (SIADH) producing euvolemic hyponatremia with inappropriately concentrated urine
C) Diabetes insipidus with dilute urine and hypernatremia
D) Primary adrenal insufficiency causing hyponatremia with hyperkalemia and hypotension
E) Pseudohyponatremia from a laboratory artifact with normal true sodium
ANSWER: B
Rationale:
The combination of hyponatremia, low serum osmolality, inappropriately concentrated urine (urine osmolality above 100 mOsm/kg when serum osmolality is low), and clinical euvolemia is the classic picture of the syndrome of inappropriate antidiuretic hormone secretion (SIADH). Vincristine can disrupt the hypothalamic-neurohypophyseal axis and cause dysregulated antidiuretic hormone (vasopressin) release independent of plasma osmolality. Management is fluid restriction, with careful correction using hypertonic saline reserved for symptomatic severe hyponatremia.
Option A: Option A is incorrect: cerebral salt wasting produces true volume depletion, whereas this patient is euvolemic.
Option C: Option C is incorrect: diabetes insipidus produces dilute urine and a tendency to hypernatremia, the opposite of this concentrated-urine, hyponatremic picture.
Option D: Option D is incorrect: adrenal insufficiency typically causes hyperkalemia and hypotension and does not fit a euvolemic, concentrated-urine SIADH pattern.
Option E: Option E is incorrect: pseudohyponatremia is a measurement artifact with normal true sodium and normal serum osmolality, not the low-osmolality state described.
12. Before conventional (Cremophor EL-based) paclitaxel infusion, patients receive a standard three-drug premedication regimen to reduce the incidence of severe hypersensitivity reactions. Which three-drug combination is the standard premedication?
A) A corticosteroid (dexamethasone), an H1 antihistamine (diphenhydramine), and an H2 antagonist (such as ranitidine or cimetidine)
B) Epinephrine, hydrocortisone, and inhaled albuterol given prophylactically
C) Acetaminophen, an H1 antihistamine, and ondansetron
D) Two H1 antihistamines plus a leukotriene receptor antagonist
E) A proton pump inhibitor, a corticosteroid, and aprepitant
ANSWER: A
Rationale:
The standard premedication for conventional paclitaxel is a corticosteroid plus an H1 antihistamine plus an H2 antagonist: dexamethasone (for example 20 mg given at 12 and 6 hours before infusion), diphenhydramine 50 mg intravenously, and an H2 antagonist such as ranitidine or cimetidine about 30 minutes before infusion. Each component targets a distinct part of the Cremophor EL anaphylactoid reaction: dexamethasone suppresses mediator release and is the most important component, the H1 antihistamine blocks urticaria and bronchoconstriction, and the H2 antagonist blunts the hypotension and flushing. This regimen reduces severe reactions to roughly 1 to 2%.
Option B: Option B is incorrect: epinephrine and albuterol are treatments for an established reaction, not the standard scheduled premedication.
Option C: Option C is incorrect: acetaminophen and ondansetron do not address the histamine-mediated hypersensitivity that the protocol targets.
Option D: Option D is incorrect: the standard regimen pairs an H1 with an H2 antagonist and a corticosteroid, not two H1 agents plus a leukotriene blocker.
Option E: Option E is incorrect: a proton pump inhibitor and aprepitant (an antiemetic agent) are not the standard hypersensitivity premedication.
13. When conventional paclitaxel is administered, the infusion must be delivered through non-PVC (non-polyvinyl chloride) tubing. What is the reason for this requirement?
A) Paclitaxel chemically degrades on contact with any plastic surface and must run through glass-lined tubing
B) PVC tubing binds and removes paclitaxel from solution, leading to underdosing
C) The Cremophor EL vehicle leaches DEHP (a plasticizer) from PVC tubing at clinically significant concentrations
D) Non-PVC tubing is required only to prevent bacterial colonization of the line
E) PVC tubing alters the pH of the solution and precipitates the drug
ANSWER: C
Rationale:
Conventional paclitaxel must be infused through non-PVC tubing because its Cremophor EL (polyoxyethylated castor oil) vehicle leaches DEHP (di(2-ethylhexyl) phthalate), a plasticizer, from polyvinyl chloride tubing at clinically significant concentrations. This is a direct consequence of the surfactant vehicle and is the same vehicle responsible for the anaphylactoid hypersensitivity reactions, tying the formulation's two major administration precautions to a single cause.
Option A: Option A is incorrect: the issue is plasticizer leaching from the tubing into the infusion, not degradation of paclitaxel requiring glass tubing.
Option B: Option B is incorrect: the clinical concern is DEHP entering the patient, not loss of drug to the tubing causing underdosing.
Option D: Option D is incorrect: non-PVC tubing is required because of DEHP leaching, not for infection control.
Option E: Option E is incorrect: the requirement is not due to a pH change or drug precipitation in PVC tubing.
14. Cabazitaxel was specifically developed to address a common mechanism of taxane resistance and has an established role in a particular clinical setting. Which statement best describes cabazitaxel?
A) It is a vinca alkaloid that overcomes resistance by binding a novel tubulin site
B) It reverses resistance by directly inhibiting beta-III tubulin synthesis
C) It is used only as first-line therapy before any docetaxel exposure
D) It has low affinity for P-glycoprotein, allowing it to overcome P-gp-mediated taxane resistance, and is used in castration-resistant prostate cancer after prior docetaxel
E) It is a hormonal agent that lowers testosterone rather than a cytotoxic drug
ANSWER: D
Rationale:
Cabazitaxel is a semisynthetic taxane developed specifically to overcome P-glycoprotein (P-gp)-mediated taxane resistance. P-gp is an efflux transporter that pumps conventional taxanes out of tumor cells and lowers intracellular drug levels; cabazitaxel has low affinity for P-gp and therefore can reach cytotoxic intracellular concentrations in P-gp-overexpressing cells. It is approved for castration-resistant prostate cancer after prior docetaxel-based therapy, where it improved overall survival versus mitoxantrone. Its dose-limiting toxicities are myelosuppression (with a high rate of febrile neutropenia, warranting primary G-CSF prophylaxis) and peripheral neuropathy.
Option A: Option A is incorrect: cabazitaxel is a taxane that binds the taxane domain, not a vinca alkaloid binding a novel site.
Option B: Option B is incorrect: it overcomes resistance by evading P-gp efflux, not by inhibiting beta-III tubulin synthesis.
Option C: Option C is incorrect: its established role is after prior docetaxel, not as pre-docetaxel first-line therapy.
Option E: Option E is incorrect: cabazitaxel is a cytotoxic microtubule-stabilizing drug, not a hormonal (androgen-lowering) agent.
15. Vinca alkaloids are vesicants, and extravasation during intravenous administration can cause severe local tissue injury. What is the appropriate local management of vinca alkaloid extravasation?
A) Immediate application of ice packs and intradermal corticosteroid injection
B) Hyaluronidase infiltration to disperse the drug, combined with warm compress application
C) Cold compresses with topical dimethyl sulfoxide, the same approach used for anthracycline extravasation
D) Prompt surgical excision of the entire infiltrated area as the first-line measure
E) Observation only, since vinca alkaloid extravasation does not cause tissue necrosis
ANSWER: B
Rationale:
Vinca alkaloids are vesicants, and extravasation can cause severe local tissue necrosis. The appropriate management is hyaluronidase infiltration, which disperses the extravasated drug, combined with warm compress application to enhance dispersion and absorption. This warm-and-disperse approach is the opposite of the cold-and-localize strategy used for some other agents, which is a common point of confusion.
Option A: Option A is incorrect: cold packs are not the recommended approach for vinca alkaloid extravasation, where warm compresses and hyaluronidase are used to disperse the drug.
Option C: Option C is incorrect: cold compresses with dimethyl sulfoxide is an anthracycline extravasation approach, not the vinca alkaloid approach, and applying it here would be the wrong strategy.
Option D: Option D is incorrect: immediate surgical excision is not the first-line measure; prompt pharmacologic management with hyaluronidase and warm compresses is.
Option E: Option E is incorrect: vinca alkaloids are vesicants and do cause tissue necrosis, so observation alone is inappropriate.
16. Ixabepilone is an epothilone analog used after failure of anthracycline and taxane therapy in breast cancer. What property explains its activity in taxane-resistant tumors?
A) It depolymerizes microtubules, the opposite mechanism of the taxanes, so taxane resistance does not apply
B) It is a hormonal agent and therefore bypasses cytotoxic resistance mechanisms entirely
C) It is highly dependent on P-glycoprotein for cellular entry, which increases its potency in resistant cells
D) It works only in tumors that lack beta-III tubulin expression
E) It stabilizes microtubules like taxanes but retains activity against tumors resistant through beta-III tubulin overexpression or P-glycoprotein efflux
ANSWER: E
Rationale:
Ixabepilone is a semisynthetic epothilone B analog that binds the same beta-tubulin site as the taxanes and stabilizes microtubules by the same mechanism, yet it is structurally unrelated to the taxane diterpenes. This structural difference lets it retain activity against the two most clinically relevant taxane resistance mechanisms: overexpression of the beta-III tubulin isotype (which lowers taxane binding affinity) and overexpression of P-glycoprotein (since ixabepilone is a poor P-gp substrate). It is formulated in Cremophor EL, so it requires the same three-drug premedication and non-PVC tubing precautions as conventional paclitaxel.
Option A: Option A is incorrect: ixabepilone stabilizes microtubules like a taxane; it does not depolymerize them.
Option B: Option B is incorrect: it is a cytotoxic microtubule-stabilizing agent, not a hormonal agent.
Option C: Option C is incorrect: ixabepilone is a poor P-gp substrate, which is precisely why it evades P-gp-mediated efflux, the opposite of depending on P-gp for entry.
Option D: Option D is incorrect: ixabepilone retains activity even in beta-III tubulin-overexpressing tumors rather than being limited to tumors lacking that isotype.
17. Building on the fatal consequences of inadvertent intrathecal vinca alkaloid administration, a set of mandatory system-level safeguards has been adopted internationally to prevent this error. Which safeguard most directly makes intrathecal administration physically impossible?
A) Dispensing vinca alkaloids only in a minibag (for example 25 to 50 mL of saline) rather than in a syringe, making them physically incompatible with intrathecal administration hardware
B) Requiring a second nurse to verbally confirm the route before any chemotherapy injection
C) Limiting vinca alkaloid dosing to once-weekly schedules to reduce total exposure
D) Storing vinca alkaloids in a refrigerator separate from other chemotherapy agents
E) Requiring written informed consent specific to vinca alkaloid therapy
ANSWER: A
Rationale:
The most direct engineering safeguard is to dispense vinca alkaloids only in a minibag (typically 25 to 50 mL of normal saline) rather than in a syringe. Intrathecal injections are given by syringe, so packaging the vinca alkaloid in a minibag makes it physically incompatible with intrathecal administration hardware. This is one of the four non-negotiable safeguards, alongside prominent For Intravenous Use Only warning labeling, sealed outer overpackaging, and separating intrathecal and intravenous procedures in time and location. These are mandatory requirements derived from fatal real-world events, not preferences.
Option B: Option B is incorrect: verbal confirmation is a useful human check but relies on attention and does not physically prevent the error the way minibag packaging does.
Option C: Option C is incorrect: changing the dosing schedule does not address the route-of-administration error at all.
Option D: Option D is incorrect: refrigerated storage location does not prevent an intrathecal route error.
Option E: Option E is incorrect: informed consent addresses the decision to treat, not the physical prevention of a wrong-route administration.
18. A patient on vincristine is started on an azole antifungal for a fungal infection. Applying what you know about vincristine metabolism, what is the expected pharmacokinetic consequence and its clinical risk?
A) Azole antifungals induce vincristine metabolism, lowering exposure and reducing efficacy
B) There is no interaction, because vincristine is eliminated unchanged by the kidney
C) Azole antifungals inhibit CYP3A4, increasing vincristine exposure and the risk of worsened neuropathy
D) The azole displaces vincristine from albumin, lowering total drug levels and toxicity
E) The combination accelerates renal clearance of vincristine, requiring a dose increase
ANSWER: C
Rationale:
Vincristine is metabolized by CYP3A4 (cytochrome P450 3A4) and is also a P-glycoprotein substrate. Azole antifungals are CYP3A4 inhibitors, so co-administration reduces vincristine metabolism, increases vincristine exposure, and raises the risk of worsened neurotoxicity. Recognizing this interaction is clinically important because vincristine's dose-limiting toxicity is neuropathy, and increased exposure directly amplifies that risk.
Option A: Option A is incorrect: azoles inhibit rather than induce CYP3A4, so exposure rises rather than falls.
Option B: Option B is incorrect: vincristine is hepatically metabolized by CYP3A4, not eliminated unchanged renally, so a metabolic interaction does occur.
Option D: Option D is incorrect: the dominant interaction is CYP3A4 inhibition increasing exposure, not protein-binding displacement lowering levels.
Option E: Option E is incorrect: the combination increases exposure through reduced metabolism; it does not accelerate clearance or justify a dose increase.
19. In combination regimens pairing paclitaxel with cisplatin, the sequence of administration affects paclitaxel pharmacokinetics and toxicity. What is the pharmacokinetic basis for giving paclitaxel before cisplatin, the standard sequence in many protocols?
A) Giving cisplatin first increases paclitaxel clearance and reduces its toxicity
B) The sequence is arbitrary, because the two drugs do not interact pharmacokinetically
C) Paclitaxel must follow cisplatin to allow cisplatin to sensitize tumor cells to microtubule stabilization
D) Giving paclitaxel before cisplatin preserves higher paclitaxel clearance and lower toxicity, because prior cisplatin impairs hepatic paclitaxel metabolism
E) Cisplatin must be given first to prevent paclitaxel from inactivating cisplatin in the bloodstream
ANSWER: D
Rationale:
The standard sequence gives paclitaxel before cisplatin. When cisplatin is given first, it impairs hepatic metabolism of paclitaxel, lowering paclitaxel clearance and increasing its toxicity. Giving paclitaxel first preserves higher paclitaxel clearance and produces lower toxicity. This is a sequence-dependent pharmacokinetic interaction, and recognizing it explains why the order of administration is specified rather than arbitrary.
Option A: Option A is incorrect: it reverses the relationship; cisplatin first lowers paclitaxel clearance and raises toxicity.
Option B: Option B is incorrect: the interaction is real and sequence-dependent, not absent.
Option C: Option C is incorrect: the rationale is a metabolic pharmacokinetic interaction, not cisplatin sensitizing cells to microtubule stabilization.
Option E: Option E is incorrect: the concern is hepatic metabolism of paclitaxel, not chemical inactivation of cisplatin in the blood.
20. A tumor that has progressed on taxane therapy is found to overexpress the beta-III tubulin isotype. Using this finding, what is the most appropriate interpretation for drug selection?
A) Beta-III tubulin overexpression increases taxane binding affinity and predicts an excellent taxane response
B) Beta-III tubulin overexpression reduces taxane efficacy, and agents such as vinca alkaloids and ixabepilone are less affected by this mechanism
C) Beta-III tubulin overexpression confers complete cross-resistance to every antimicrotubule agent, so the class should be abandoned
D) Beta-III tubulin overexpression affects only vinca alkaloids and spares the taxanes
E) Beta-III tubulin overexpression has no established relationship to antimicrotubule drug response
ANSWER: B
Rationale:
Beta-III tubulin (TUBB3) is the isotype with the lowest affinity for taxanes. Its overexpression in tumors such as non-small cell lung cancer and ovarian cancer is associated with taxane resistance and poor prognosis, because beta-III-rich microtubules are intrinsically more dynamic and bind paclitaxel less avidly. Importantly, vinca alkaloids and ixabepilone are less affected by beta-III tubulin overexpression than the taxanes, which is exactly why this finding informs rational drug selection toward an agent that retains activity.
Option A: Option A is incorrect: beta-III overexpression lowers taxane binding affinity and predicts resistance, not an excellent response.
Option C: Option C is incorrect: it does not confer complete cross-resistance across the whole class; other agents retain activity.
Option D: Option D is incorrect: it reverses the relationship, since beta-III overexpression principally reduces taxane efficacy while sparing vinca alkaloids.
Option E: Option E is incorrect: beta-III tubulin overexpression has an established association with taxane resistance.
21. Among the resistance mechanisms affecting antimicrotubule agents, one applies most broadly across both the vinca alkaloid and taxane classes and indeed across most hydrophobic anticancer drugs. Which mechanism is the most broadly applicable?
A) P-glycoprotein (encoded by ABCB1/MDR1) overexpression, an ATP-dependent efflux pump that exports paclitaxel, docetaxel, and the vinca alkaloids out of cells
B) A point mutation in the taxane-binding domain that affects taxanes only
C) Beta-III tubulin overexpression, which is specific to vinca alkaloid resistance
D) Loss of the spindle assembly checkpoint, which makes cells hypersensitive rather than resistant
E) Increased renal excretion of the drug due to upregulated tubular transporters
ANSWER: A
Rationale:
P-glycoprotein (P-gp), encoded by the ABCB1 (also called MDR1) gene, is an ATP-dependent efflux pump that transports a wide range of hydrophobic substrates out of cells, including paclitaxel, docetaxel, vincristine, vinblastine, and vinorelbine. By lowering intracellular drug accumulation below the cytotoxic threshold, it produces resistance that spans both major antimicrotubule classes and most hydrophobic anticancer drugs, making it the broadest applicable mechanism. This breadth is exactly why agents that evade P-gp, such as cabazitaxel and ixabepilone, were developed.
Option B: Option B is incorrect: a taxane-binding-domain point mutation is a target-level mechanism specific to taxanes, not broadly cross-class.
Option C: Option C is incorrect: beta-III tubulin overexpression principally reduces taxane efficacy and is not specific to vinca alkaloid resistance as stated.
Option D: Option D is incorrect: loss of the spindle assembly checkpoint does not confer the broad efflux-based resistance described.
Option E: Option E is incorrect: increased renal transporter-mediated excretion is not the established broad antimicrotubule resistance mechanism; P-gp efflux at the tumor cell is.
22. The development of nab-paclitaxel was partly justified by the hypothesis that albumin binding targets the drug to tumors overexpressing SPARC (secreted protein acidic and rich in cysteine). Applying a critical reading of the evidence, what is the current status of the SPARC-targeting rationale in clinical practice?
A) SPARC expression is now a validated, routinely used predictive biomarker that selects patients for nab-paclitaxel
B) SPARC-mediated targeting has been disproven, and nab-paclitaxel offers no advantage over conventional paclitaxel for any reason
C) SPARC expression reliably predicts conventional paclitaxel response but not nab-paclitaxel response
D) SPARC testing is required by regulators before nab-paclitaxel can be prescribed
E) The SPARC hypothesis has not been validated as a predictive biomarker; nab-paclitaxel's clearest clinical advantages are elimination of Cremophor EL-related hypersensitivity and the associated premedication requirement
ANSWER: E
Rationale:
The SPARC hypothesis proposes that albumin-bound paclitaxel is concentrated in SPARC-overexpressing tumors via albumin receptor-mediated transcytosis, offering a targeting advantage. However, prospective trials correlating SPARC expression with nab-paclitaxel response have been inconsistent, and SPARC has not been validated as a predictive biomarker in practice. The clearest clinical advantages of nab-paclitaxel are the elimination of Cremophor EL-related hypersensitivity (and its premedication and non-PVC tubing requirements) and the ability to deliver paclitaxel in a shorter infusion. Whether SPARC-mediated targeting contributes meaningfully to efficacy remains an open question.
Option A: Option A is incorrect: SPARC is not a validated, routinely used predictive biomarker for nab-paclitaxel selection.
Option B: Option B is incorrect: although SPARC targeting is unvalidated, nab-paclitaxel does retain real advantages (vehicle elimination), so the claim of no advantage is wrong.
Option C: Option C is incorrect: SPARC has not been established as a reliable predictor of conventional paclitaxel response either.
Option D: Option D is incorrect: SPARC testing is not a regulatory prerequisite for prescribing nab-paclitaxel.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.